Low-frequency right prefrontal repetitive transcranial magnetic stimulation (rTMS) appears to have antidepressant properties although the effectiveness of this treatment in clinical practice has not been assessed nor have the optimal stimulation parameters been adequately defined. A total of 130 patients with treatment-resistant depression were randomized to either 1-or 2-Hz rTMS over the right prefrontal cortex (PFC) for 2 wk with a possible further 2 wk extension. Non-responders were randomized to either 5-or 10-Hz left PFC rTMS. Overall, 66 patients (51 %) achieved response and 35 (27 %) remission criteria. For right-sided treatment, depression significantly improved but there was no between-group difference. Twenty-eight (42 %) patients in the 1-Hz group and 33 (53 %) patients in the 2-Hz group achieved response criteria (x 2 =1.40, p>0.05). Depression symptom scores also improved for patients who crossed over to left-sided treatment but there was no significant difference in response between 5-and 10-Hz rTMS. Despite a heterogeneous sample, a significant proportion of patients met clinical response criteria following treatment but response to 1 and 2 Hz did not differ. 2-Hz right PFC rTMS has antidepressant properties but offers no advantage over 1 Hz despite doubling pulse number.
Introduction
Major depressive disorder is a severe illness resulting in significant disability and morbidity. It is well recognized that a significant percentage (y30 %) of patients with depression fail to respond to standard therapies (Fava, 2003) . Over the last 10 yr a number of clinical trials of repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression (TRD) have been conducted (e.g. Berman et al., 2000 ; Fitzgerald et al., 2006 ; George et al., 1995 George et al., , 2000 Grunhaus et al., 2003 ; Padberg et al., 1999) . Most of these trials have used high-frequency rTMS, usually between 5 and 20 Hz, applied to the left dorsolateral prefrontal cortex (DLPFC). However, although most of these studies have shown antidepressant effects of active rTMS greater than sham stimulation, these differences have been of limited magnitude and considerable questions remain as to whether rTMS has clinically relevant effects (Burt et al., 2002 ; Martin et al., 2003) . These questions have arisen from the small samples in studies published to date, variability in stimulation parameters and the modest treatment effects that have been achieved. An alterative rTMS treatment paradigm, involving the provision of low-frequency stimulation to the right DLPFC has been proposed. This was initially shown to be superior to sham stimulation in treatmentresponsive patients (Klein et al., 1999) . A number of subsequent studies have explored this approach in TRD with significant differences reported over sham stimulation in two studies (Fitzgerald et al., 2003 ; Kauffmann et al., 2004) and two studies reporting similar responses to high-frequency left-sided rTMS (Fitzgerald et al., 2003 ; Isenberg et al., 2005) . Although the mechanism of action of rTMS remains unclear, low-and high-frequency stimulation are proposed to have opposite effects on cortical activity possibly underlying these clinical findings (Fitzgerald et al., 2003a) . Studies that have explored the physiological effects of low-frequency rTMS have predominately used 0.9-1.0 Hz stimulation which has been shown to produce a reduction in the excitability of local cortical regions (e.g. Chen et al., 1997 ; Chen and Seitz, 2001 ; Fitzgerald et al., 2002) . However, the stimulation boundaries as to what is meant by ' low frequency' have not been clearly defined with one report suggesting that 2-Hz stimulation may have similar effects (van Honk et al., 2003) . In animal experiments, 2-Hz stimulation has been used to produce long-term depression (LTD) of synaptic transmission in motor cortical rat brain slices (Hess and Donoghue, 1996) and LTD has been proposed to be a mechanism through which low-frequency rTMS alters cortical activity (Hoffman and Cavus, 2002) .
The current study was designed to : (1) investigate the overall clinical effectiveness of low-frequency right-sided rTMS (i.e. the proportion of responders to this type of treatment in a more real world clinical environment), (2) to further explore the stimulation parameters that would be effective in its provision, (3) to explore the therapeutic potential of 5-and 10-Hz left PFC rTMS in patients who failed to respond to rightsided rTMS in a randomized cross-over phase. We based the trial on an assumption that 2-Hz right PFC rTMS would act as ' low-frequency' stimulation and hence would have similar ' intrinsic' efficacy to 1-Hz rTMS. However, as twice as many 2-Hz pulses can be provided in the same time as 1-Hz stimulation, we hypothesized that 2-Hz rTMS, applied over an identical time period, would result in substantially enhanced clinical response consistent with the fact that we would be effectively doubling the ' dose ' based on pulse number. It is not completely clear whether there is a 'dose ' effect with rTMS based on pulse number but at the time of conception of the study this seemed likely based on reviews of clinical studies (Gershon et al., 2003) as well as the effects of low-frequency stimulation in electrophysiological experiments (Maeda et al., 2000) . Therefore, we conducted a randomized, double-blind controlled trial of the efficacy of 1-Hz vs. 2-Hz right PFC rTMS. To investigate the overall effectiveness of the technique, we included a very large sample of patients and had few exclusion criteria that would restrict patient participation. We did not include a sham control based on the trials, including our own (Fitzgerald et al., 2003 ; Kauffmann et al., 2004) , showing superiority of this form of stimulation over sham and the desire to recruit a large effectiveness sample.
Patients and methods

Study design
The study involved a two-arm double-blind, randomized controlled trial (n=130) (Figures 1 and 2 ). The trial was conducted across three hospital sites. Patients were sequentially randomized using a single computer-generated random number sequence (no stratification). The patients and raters were blind to treatment but the clinician administering rTMS was aware of the treatment group. The patients and raters were advised that there was a difference in the stimulation parameters but specifics were not described. All patients initially received 10 sessions of treatment on a daily basis, 5 d per week. After the tenth session, a blinded assessment was made. At this time patients were classified as ' initial responders ' if they had achieved a >20 % reduction of the 17-item Hamilton Depression Rating Scale (HAMD ; Hamilton, 1967) . If this was the case, they were offered a further 2 wk (10 sessions) of rTMS. Patients who failed to respond by 2 wk were offered treatment with left-sided rTMS. These patients were randomized to receive a course of either 5-or 10-Hz left PFC rTMS for 2 wk with a further 2-wk extension for patients who partially responded (same criteria as above) by 2 wk. Although the initial treatment time of 2 wk chosen was shorter than some of the more recently conducted rTMS trials (e.g. Fitzgerald et al., 2006) , the design was chosen to provide the opportunity for up to 4 wk of right-sided treatment as well as the possibility of a trial of leftsided treatment in the case of non-response but limiting the overall duration to 6 wk.
Subjects
A total of 130 patients participated (47 male, 83 female, age range 22-82 yr, mean 49.4¡13.9 yr). Diagnosis was determined using the MINI (Sheehan et al., 1998) by a study psychiatrist. There were 43 patients with major depressive disorder -single episode, 62 patients with major depressive disorder -relapse, 14 with bipolar I disorder -depressive episode and 11 with bipolar II disorder -depressive episode. Comorbid diagnoses were also recorded using the MINI. The presence of comorbid borderline personality disorder was based in the clinical diagnosis of the referring psychiatrist confirmed by a study psychiatrist.
Patients were recruited by referral from a number of private psychiatrists between May 2004 and January 2006. All patients were in-patients during the trial which was conducted across three private psychiatric hospitals in Victoria, New South Wales and Queensland. Training in the TMS methods, trial management and ratings were conducted by the lead study site. This involved reciprocal visits between the sites by both psychiatric and nursing staff involved in study procedures. For the sites in New South Wales and Queensland, this included a week of training in methods for TMS administration in Victoria followed by a review of skills at the 'home ' site.
The sample size was determined for the second study objective, investigating differences between 1-and 2-Hz rTMS. The study was powered (0.92) to show a five-point difference in the study end-point variable between the groups (a<0.05, s=8) with a planned sample size of 120. This difference is small but we believed that it was unlikely that a trial of two active treatments in a treatment-resistant population would be likely to show greater differences. However, the study would have considerably greater power to demonstrate more robust effects. In total, 130 patients were recruited to allow for a small dropout rate (5-10 %).
Patients were included if they were experiencing moderate to severe depression [scoring >16 (Bech et al., 1986) on the 17-item version of HAMD]. Patients were excluded with significant currently active medical illnesses, current neurological disease or a contraindication to rTMS (for example a history of a seizure disorder, the presence of a pacemaker or metal somewhere in the head other than the teeth). Patients with a current DSM-IV diagnosis of alcohol or substance dependence were excluded due to concerns about seizure risk but patients with other concurrent Axis I psychiatric disorders were not excluded.
All patients had failed to respond to a minimum of two courses of antidepressant medications for at least 6 wk in the current episode (Stage II, Thase and Rush Definition ; Thase and Rush, 1997) (mean number of courses 5.44¡3.6). Medications were not allowed to have changed in the 4 wk prior to commencement of the trial or during the trial itself. In total, 117 patients were taking antidepressant medication during the study and 55 were receiving concurrent treatment with a mood stabilizer.
After complete description of the study to the subjects, written informed consent was obtained from all patients and the study received the appropriate Human Research Ethics committee approval. 
TMS treatment
rTMS was administered with a Medtronic Magpro30 magnetic stimulator (Medtronic Inc., Minneapolis, MN, USA) using stand-held 70-mm figure-of-eight coils. The coil was held tangential to the scalp with the handle pointing back and away from the midline at 45x. The site of stimulation during the TMS treatment sessions was defined by a point 5 cm anterior to that required for maximum stimulation of the abductor pollicis brevis muscle. The resting motor threshold (RMT) was measured bilaterally using standard visual methods (Pridmore et al., 1998) . Patients sat in a comfortable reclining chair during treatment. There was limited interaction with the treater and they were allowed to listen to music played on a radio in the room.
The TMS conditions are summarized in Table 1 . Right PFC stimulation in both arms of the trial (i.e. 1 and 2 Hz) was provided in one continuous 15-min train with occasional brief breaks to allow the interchange of coils for cooling. Stimulation between these two groups was matched for treatment time but not for number of stimulations. Stimulation was provided at 110 % of the RMT. Left-sided rTMS was provided in 30 trains, at 100 % of the RMT and for either 5 s (10-Hz group) or 10 s (5-Hz group) duration per train. The lower intensity was used for left-sided treatment due to the greater degree of discomfort with this type of stimulation. There was a 25-s (10-Hz group) or 20-s (5-Hz group) inter-train interval. As described in the Introduction, for right-sided treatment we chose to match administration time rather than pulse number to investigate a possible enhancement of efficacy with 2-Hz stimulation. In contrast, in the cross-over phase our primary objective was to investigate whether the lower frequency arm (5 Hz) had similar efficacy to 10-Hz stimulation and hence we matched stimulation characteristics as much as possible. Given that in our experience 5 Hz is better tolerated than 10 Hz, we considered that a demonstration of similar response would suggest that this is a viable option for highfrequency treatment.
Clinical assessment
The primary outcome measure for the study was scores on the 17-item version of the HAMD (Hamilton, 1967) . In addition, all patients completed the Beck Depression Inventory (BDI ; Beck et al., 1961) .
Data analysis t tests and x
2 tests were used to investigate differences between the groups on demographic and baseline clinical variables. Consistent with our intent to explore clinical effectiveness, all the main analyses in both the initial and cross-over phases of the study were conducted with data using the last observation carried forward method. Although there was a large 'dropout ' rate at 2 wk attributable to the study design, as this did not systematically bias between the treatments arms, the method was considered appropriate. The primary analysis was conducted of the difference in change scores from baseline to week 2 (total group) and from baseline to week 4 for all subjects using repeated-measures ANOVA models. A secondary analysis of the same data was conducted to investigate whether there was an effect of treatment site on outcome (as an additional between-subjects factor). In addition, the analysis was repeated for the separate data from each site. The same methods were used to study differences in response on the BDI and for the left PFC rTMS cross-over phase. x 2 tests were used to investigate differences in the proportion of patients achieving response (>50 % reduction in HAMD score) and remission (HAMD scores <8) criteria between the groups. To investigate predictors of response to treatment, we conducted a logistical regression analysis with response to right-sided treatment as the dependent variable. Predictors entered included, age, sex, diagnosis, comorbidity, current antidepressant and mood stabilizer medication, number of past antidepressant medication trials and baseline HAMD score. All procedures were two-tailed and significance was set at an a-level of 0.05. All statistical analysis was conducted with SPSS for Windows v. 11.5 (SPSS Inc., Chicago, IL, USA).
Results
Patients
Baseline clinical characteristics are summarized in Table 2 . There were no significant baseline differences between the groups. Of the total sample, only two failed to complete the initial 2 wk treatment (both withdrawn due to withdrawal of consent). Both had experienced no change or mild deterioration prior to withdrawal. Of the 128 patients who completed 2 wk treatment, 86 met criteria to continue treatment for a further 2 wk. Sixty-eight of these elected to continue (31 in the 1-Hz group, 37 in the 2-Hz group) and all completed the additional 2 wk treatment. The patients who elected not to continue did so for a number of reasons including satisfaction with therapeutic response (5), dissatisfaction with therapeutic response (4) and practical impediments to continuation (9). Overall treatment was tolerated very well with no significant adverse events. One patient developed a hypomanic episode soon after completion of phase 1 treatment.
Overall outcome/effectiveness
By study end, including data from the initial trial and the cross-over phase, 66 patients from the total sample (51 %) achieved response and 35 (27 %) achieved remission criteria.
Primary outcome analysis : continuous data
In the first 2 wk of the trial, there was a significant improvement in HAMD and BDI scores but no significant difference in response between the groups : there was a mean change in HAMD scores of 26.1¡31.1 % in the 1-Hz group and 30.1¡36.4 % in the 2-Hz group. There was a significant effect of time [F(1, 128 At study end there was a 33.7¡38.0 % change in the 1-Hz group and a 39.4¡41.7 % change in the 2-Hz group (HAMD scores). Considering just the patients who received 4 wk treatment, at study end there was a 62.3¡24.0 % change in the 1-Hz group (n=31) and a 64.7¡21.0 % change in the 2-Hz group (n=37). When added to the repeated-measures ANOVA models, there was no significant effect of site or siterTMSrgroup interaction [F(4, 248)=0.54, p>0.05]. When analysed separately, we found a significant effect of time and no grouprtime interaction for all three sites.
Categorical analysis
Thirty-eight patients (29 %) met full response criteria (>50 % reduction in HAMD scores) at 2 wk and 61 (47 %) by the end of 4 wk of right-sided rTMS. There was no difference in the proportion of patients meeting response criteria at 2 wk (x 2 =0.38, p>0.05) or 4 wk (x 2 =0.14, p>0.05) (Table 3 ) between the two groups. Including patients who met response criteria after 2 wk treatment and did not continue and patients who received 4 wk treatment, a total of 28 (42 %) patients in the 1-Hz group and 33 (53 %) patients in the 2-Hz group achieved response criteria by the end of their participation (x 2 =1.40, p>0.05). A total of 13 patients in the 1-Hz group and 20 patients in the 2-Hz group achieved remission by study end (x 2 =2.6, p=0.11).
Cross-over data
Thirty patients received left-sided rTMS (16 at 5 Hz and 14 at 10 Hz). There was a significant (Table 4 ). There was a mean improvement of 20.6¡ 25.2 % in the 5-Hz group and 32.9¡31.6 % in the 10-Hz group. Four patients in the 10-Hz group (28 %) and one patient in the 5-Hz group (6 %) met response criteria (Fischer's exact test, p=0.16).
Predictors of response
The final multivariate model from the logistical regression analysis is presented in Table 5 . The only predictor of response was the presence of a comorbid personality disorder (compared to the presence of no comorbidity) which was negative predictor of response. There was no relationship between age and response. 
Bipolar disorder patients
Discussion
The main finding of this study was that y50 % of patients achieved clinical response criteria and there appeared to be no difference in response rates between 1-and 2-Hz right PFC rTMS. This response rate was achieved in a relatively heterogeneous and substantial cohort of patients with TRD suggesting that lowfrequency right-sided rTMS has significant clinical utility. The low dropout rate during the initial 2-wk period of treatment implies that treatment was generally well tolerated and acceptable for patients. In addition, we found that a proportion of patients did respond to left-sided treatment despite failure to respond to right-sided rTMS in the initial phase but there was no significant difference in response between 5-and 10-Hz rTMS.
There are several implications of the results of the study. First, and perhaps most importantly, rightsided rTMS appeared overall to have a reasonable degree of effectiveness in this group of patients. Although the study contained a randomized design and required standard consent and trial procedures, the inclusion and exclusion criteria were much less restrictive than standard clinical trials, especially in regards to the inclusion of patients with comorbid Axis I disorders, and we included a considerably Mean Hamilton Depression Rating Scale (HAMD) and Beck Depression Inventory (BDI) scores for each study visit in the cross-over phase with the last observation data carried forward for each data-point.
larger sample than has been included in previous published clinical trials of rTMS. This enhances our capacity to generalize these findings to broader groups of patients with TRD. The overall response rate (especially considering both phases of the trial) was robust with 50 % of subjects who completed the study experiencing a TRD achieving response criteria. As rTMS is very well tolerated and appears quite acceptable to patients (Walter et al., 2001) , this degree of response is probably of sufficient size to make the treatment a viable option for many patients with TRD. In addition, there are still modifications of the application of rTMS (e.g. Fitzgerald et al., 2006) , that may enhance overall effectiveness increasing the clinical utility of the technique. The similar response to treatment with 1-and 2-Hz rTMS in the right-sided treatment protocol was counter to our hypothesis. We had considered that based on the animal studies (e.g. Hess and Donoghue, 1994) 2-Hz rTMS should be effective at reducing cortical excitability (i.e. act as low-frequency stimulation). If this is the case, we presumed that the greater number of pulses provided would result in enhanced efficacy. There are a number of reasons why this may have not been the case. First, they may be a ceiling effect to rTMS response above which increasing the dose, for example the pulse number or stimulation intensity, may have no effect. Second, the study may have been underpowered to show a small difference between the treatments. Whilst this may well have been the case, we felt a difference of 5 points in outcome scores was a reasonable and clinically relevant effect size and more subtle differences only apparent with much larger samples may have limited clinical relevance anyway.
Third, 1-Hz stimulation may be fundamentally more effective and the advantage of increasing pulse number with the 2-Hz treatment may have been outweighed by this stimulation frequency being less effective. This could only be resolved by conducting a similar study with the same frequency groups but with the same numbers of pulses per group. With the assumption that reducing right-sided cortical excitability is one of the mechanisms mediating therapeutic efficacy with rTMS, one reason why 2-Hz stimulation may be less effective is that it may produce a less pronounced change in cortical excitability. Few studies have explored the physiological responses to 2-Hz stimulation in humans. Jennum et al. (1995) reported that 2-Hz stimulation resulted in increased motor-evoked potential (MEP) size but this was within a stimulation train only. Romeo et al. (2000) reported no change in MEP amplitude following such stimulation. Short trains of 1-and 2-Hz stimulation have been shown to produce different effects on cortical inhibition as measured by the cortical silent period, with 2-Hz but not 1-Hz stimulation, having effects similar to higher frequencies (Romeo et al., 2000) . In addition, it is well recognized that although 1-Hz stimulation results in reduced cortical excitability, this is a group effect and there is considerable interindividual variation with some individuals displaying an increase rather than decrease in excitability in response to 1-Hz stimulation (Maeda et al., 2000) . Therefore it is possible that there is increased variation in responses to 2-Hz stimulation between individuals, that is, a greater proportion of people experience increases in cortical excitability with 2-Hz stimulation than is seen with 1 Hz. This could relate to the fact that 2 Hz, being of higher stimulation frequency, should be closer to the ' threshold ' that must exist between increasing vs. decreasing cortical excitability. Despite these specific considerations, it may well be possible that frequency is of less significance than has been traditionally considered. Studies have reported antidepressant effects of both high-and low-frequency stimulation applied to the left PFC (e.g. Kimbrell et al., 1999 ; Speer et al., 2000) and our data suggests that effects on the right may also occur over a wider frequency spectrum than traditionally considered. It may well be possible that the effects of rTMS primarily relate to repeated stimulation, for example altering cortical-subcortical connectivity, rather than local alterations in cortical excitability.
It was of interest that there was no relationship between age and response to rTMS. Thirty-three of our patients were over the age of 60 yr. Several previous studies have suggested that response rates to leftsided rTMS with increased age are lower (Nahas et al., 2004) although no studies to date have investigated the relationship of age and response to right-sided rTMS. The association of comorbid personality disorder to poorer outcome is not surprising given that this comorbidity appears related to poorer response to other biological treatments of depression (Thase, 1996) .
Our study did suggest that there was little difference in response to 5-or 10-Hz left-sided stimulation. However, given the small numbers this may have just been an issue of study power, especially as there is a suggestion in the data of a possible advantage in the 10-Hz group in regards to response rates. However, considering left treatment as a whole, it is of potential clinical significance that a group of patients who failed to respond to right-sided low-frequency rTMS responded to left-sided high-frequency rTMS. Previous research has indicated that the two forms of treatment have similar efficacy (Fitzgerald et al., 2003 ; Isenberg et al., 2005) but no substantial sample of patients have been studied crossing over between treatments after failed response. Three (out of 10) patients in our previous study achieved response criteria when treated with 10-Hz left rTMS after failing treatment with 1-Hz stimulation on the right (Fitzgerald et al., 2003) . The current data argues that a trial of left-sided treatment is justified after failed right-sided treatment in a clinical setting. The better tolerability and less strain on equipment posed by low-frequency stimulation suggests that this may be a better ' first choice ' form of stimulation than high-frequency left PFC rTMS (Fitzgerald et al., 2003) . However, both of these forms of stimulation may eventually be supplanted by other novel approaches such as sequential bilateral stimulation (Fitzgerald et al., 2006 ).
An interesting but highly preliminary finding was our observation of potentially enhanced responses to 2-Hz stimulation in the patients with bipolar affective disorder (BPAD) Few studies have explored the effects of rTMS in BPAD (Nahas et al., 2003) and no studies have investigated the effects of right-sided lowfrequency stimulation in a significant sample of subjects. The largest BPAD trial (n=23) failed to find significant differences between active and sham stimulation using left high-frequency stimulation (Nahas et al., 2003) . Although there have been reports of anti-manic effects of right-sided high-frequency stimulation (Grisaru et al., 1998 ; Kaptsan et al., 2003 ; Michael and Erfurth, 2004 ; Saba et al., 2004) , these have not all been positive (Kaptsan et al., 2003) . Given the clinical challenges in the management of bipolar depression, further investigation of 2-Hz right-sided stimulation in a sham controlled trial would seem warranted.
There are a number of important limitations on the interpretation of the results of this study. First, it would have been of considerable interest to compare the same number of 1-and 2-Hz pulses in addressing the question of whether 2-Hz stimulation has equivalent treatment effects (and hence whether frequency really matters at all). However, our primary focus was on the clinical question of whether we could increase efficacy and it was not possible to address both of these questions in the one study. A second limitation is the lack of a sham control which does not allow us to control for confounding effects including the effect of hospitalization. However, the collection of large 'effectiveness ' samples is a complementary approach to the conduct of sham controlled trials and this study was based on previous research clearly showing the benefit of low-frequency right PFC over sham stimulation (Fitzgerald et al., 2003 ; Klein et al., 1999) . In addition, the degree of treatment resistance of the sample probably limits the degree of placebo response. An additional limitation lies in our failure to collect long-term follow-up data. Depression is a relapsing condition and it will be critical to build on the limited studies to date that have investigated the impact of rTMS courses on long-term outcomes (e.g. Dannon et al., 2002) . In addition, we collected inadequate information on the duration of depressive illness and past ECT history to confidentially include these variables in our predictive models. Finally, we did not collect information on the integrity of the blinding of the subjects and raters. However, given the nature of the study hypotheses in regard to different responses between the groups and the nature of the information provided in the consent process, subjects are unlikely to have formed strong beliefs about the likelihood of response to one or other of the groups.
In conclusion, low-frequency right-sided rTMS produced a clinically relevant response rate in a large representative sample of patients with TRD. There was no difference in response between 1-and 2-Hz stimulation. Finally, a moderate but significant percentage of patients who failed to respond subsequently responded to high-frequency left-sided rTMS at either 5 or 10 Hz.
